Capstone Therapeutics Corporation has entered into a significant stock purchase agreement with an accredited investor, involving the potential sale of up to $20 million in common stock. Under the terms of this agreement, Capstone has the option to sell shares to the investor, priced at 97% of the lowest daily volume-weighted average price over a three-day period. Additionally, a recent amendment to this agreement has increased the limits on the volume and dollar amount of shares that can be purchased in a single transaction. This amendment allows for a maximum purchase of up to 40% of the trading volume or $3 million, whichever is lower, enhancing Capstone's financial flexibility and capital-raising options.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。